Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MT-238
- Development stage
- Preclinical
- Lead developer
- Mito BioPharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MT-238 is a preclinical-stage small molecule mitochondrial uncoupler developed by Mito BioPharm for the treatment of non-alcoholic steatohepatitis (NASH) and cancer. Developed using the company's proprietary 'miunins' platform, MT-238 acts as a functional mimetic of mitochondrial uncoupling proteins UCP1 and UCP2/3. By dissipating the proton gradient across the inner mitochondrial membrane, MT-238 uncouples oxidative phosphorylation from ATP synthesis, forcing cells to increase substrate oxidation and energy expenditure. This mechanism reduces ectopic lipid accumulation in the liver to address metabolic dysfunction in NASH, while also disrupting the metabolic biomass production required for rapid cell proliferation in cancer cells.
Beyond the preview
Go deeper on MT-238.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MT-238.